uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts [Yahoo! Finance]
Erasca, Inc. (ERAS)
Company Research
Source: Yahoo! Finance
Syndax (SNDX) raised to $45, trades at $23.23, Q4 revenue $44.20M up 38%; Erasca (ERAS) gets $24 target, up 305.17% YTD. uniQure's FDA regulatory path improves after Vinay Prasad's departure, while Syndax's IPF optionality and Erasca's RAS inhibitor readout remain underpriced. The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure ( NASDAQ:QURE ), Syndax Pharmaceuticals ( NASDAQ:SNDX ), and Erasca ( NASDAQ:ERAS ) share a common thread: analysts see asymmetric upside in names where the market has not yet priced in the full probability of success. uniQure: Two Upgrades, One Regulatory Shift The most dramatic call belongs to uniQure. RBC Capital analyst Luca Issi upgraded the stock to Outperform from Sector Perform with a price target of $35, up from $11. Wells Fargo also upgraded uniQ
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't [Yahoo! Finance]Yahoo! Finance
- Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) Adds 13%; Soars 310% YTD [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) had its price target raised by JPMorgan Chase & Co. from $24.00 to $25.00. They now have an "overweight" rating on the stock.MarketBeat
- Erasca (ERAS) had its price target raised by Guggenheim from $12.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 3/16/26 - Form 144
- 3/12/26 - Form 10-K
- 3/12/26 - Form 8-K
- ERAS's page on the SEC website